Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection

Clinical Infectious Diseases

Volumn 43, Issue 3, 2006, Pages 271-275

  Cook, Paul P ^a   Maldonado, Ricardo A ^a   Yarnell, Connie T ^c   Holbert, Don ^b  

^a EAST CAROLINA UNIVERSITY   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

^c Pitt County Health Department   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ANOREXIA; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEPATITIS; HUMAN; JAUNDICE; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT COURSE THERAPY; TREATMENT OUTCOME; VOMITING; WORLD HEALTH ORGANIZATION;

ADULT; ANTITUBERCULAR AGENTS; FEMALE; HEPATITIS, TOXIC; HUMANS; MALE; PATIENT COMPLIANCE; PYRAZINAMIDE; RIFAMPIN; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 33746034591     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/505398     Document Type: Article

References (23)

1. Horsburgh CR. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004; 350:2060-7.
2. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000; 49(RR-6):1-51.
3. Tulsky JP, Pilote L, Hahn JA, Zolopa AJ, Burke M, Chesney M, Moss AR. Adherence to isoniazid prophylaxis in the homeless: a randomized controlled trial. Arch Intern Med 2000; 160:697-702.
4. LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis in a public health clinic. Am J Respir Crit Care Med 2003; 168:443-7.
5. Jasmer RM, Saukkonen JJ, Blumberg HM. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002; 137(8):640-7.
6. Centers for Disease Control and Prevention. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: New York and Georgia, 2000. MMWR Morb Mortal Wkly Rep 2001; 50:289-91.
7. Centers for Disease Control and Prevention. Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revision in American Thoracic Society/CDC recommendations: United States, 2001. MMWR Morb Mortal Wkly Rep 2001; 50:733-5.
8. Lobato MN, Reves RR, Jasmer RM, Grabau JC, Bock NN, Shang N. Adverse events and treatment completion for latent tuberculosis in jail inmates and homeless persons. Chest 2005; 127:1296-303.
9. McElroy PD, Ijaz K, Lambert LA, et al. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis 2005; 41:1125-33.
10. Ijaz K, Jereb JA, Lambert LA, et al. Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis 2006; 42:346-55.
11. Centers for Disease Control and Prevention, American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161:5221-47.
12. World Health Organization (WHO) antiretroviral therapy adverse drug reaction terminology. Geneva: WHO Collaborating Center for Drug International Monitoring, 1979.
13. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America. Controlling tuberculosis in the United States. Am J Respir Crit Care Med 2005; 172:1169-227.
14. McNeil L, Allen M, Estrada C, Cook P. Pyrazinamide and rifampin vs. isoniazid for the treatment of latent tuberculosis. Chest 2003; 123: 102-6.
15. Lee AM, Mennone JZ, Jones RC, Paul WS. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. Int J Tuberc Lung Dis 2002; 6:995-1000.
16. Narita M, Kellman M, Franchini DL, McMillan ME, Hollender ES, Ashkin D. Short course rifamycin and pyrazinamide treatment for latent tuberculosis infection in patients with HIV infection. Chest 2002; 122:1292-8.
17. Bock NN, Rogers T, Tapia JR, Herron GD, DeVoe B, Geiter LJ. Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates. Chest 2001; 119:833-7.
18. Stout JE, Engemann JJ, Cheng AC, Fortenberry ER, Hamilton CD. Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. Am J Respir Crit Care Med 2003; 167:824-7.
19. Hong Kong Chest Service, Tuberculosis Research Centre, Madras, and British Medical research Council. A double-blind placebo controlled trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992; 145:36-41.
20. Geiter LJ, Results of a randomized, controlled trial to assess the toxicity and patient adherence with two short course regimens for the prevention of tuberculosis, a two month regimen of rifampin and pyrazinamide or a four-month regimen of rifampin only, in comparison with a control regimen of six-months isoniazid. PhD. (Epi) Thesis. Baltimore: School of Hygiene and Public Health, John Hopkins University, 1997:180.
21. Younossian AB, Rochat T, Ketterer J-P, Wacker J, Janssens J-P. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur Respir J 2005; 26:462-4.
22. Lee AM, Mennone JZ, Jones RC, Paul WS. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. Int J Tuberc Lung Dis 2002; 6:995-1000.
23. Al Sarraf KA, Michielsen PP, Hauben EI, et al. Hepatotoxicity after a short course of low-dose pyrazinamide. Acta Gastroenterol Belg 1996; 59:251-3.